Bronchiolitis Obliterans Syndrome (BOS), Bronchiolitis Obliterans Organizing Pneumonia (BOOP), and Other Late-Onset Noninfectious Pulmonary Complications following Allogeneic Hematopoietic Stem Cell Transplantation

Satoshi Yoshihara, Gregory Yanik, Kenneth R. Cooke, Shin Mineishi

Research output: Contribution to journalReview articlepeer-review

Abstract

Pulmonary dysfunction is a significant complication following allogeneic hematopoietic stem cell transplantation (HSCT), and is associated with significant morbidity and mortality. Effective antimicrobial prophylaxis and treatment strategies have increased the incidence of noninfectious lung injury, which can occur in the early posttransplant period or in the months and years that follow. Late-onset noninfectious pulmonary complications are frequently encountered, but diagnostic criteria and terminology for these disorders can be confusing and therapeutic approaches are suboptimal. As a consequence, inaccurate diagnosis of these conditions may hamper the appropriate data collection, enrollment into clinical trials, and appropriate patient care. The purpose of this review is to clarify the pathogenesis and diagnostic criteria of representative conditions, such as bronchiolitis obliterans syndrome and bronchiolitis obliterans organizing pneumonia, and to discuss the appropriate diagnostic strategies and treatment options.

Original languageEnglish (US)
Pages (from-to)749-759
Number of pages11
JournalBiology of Blood and Marrow Transplantation
Volume13
Issue number7
DOIs
StatePublished - Jul 2007

Keywords

  • Allogeneic
  • Bronchiolitis obliterans organizing pneumonia (BOOP)
  • Bronchiolitis obliterans syndrome (BOS)
  • Diagnostic criteria
  • Late-onset noninfectious pulmonary complications
  • Pathogenesis

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Bronchiolitis Obliterans Syndrome (BOS), Bronchiolitis Obliterans Organizing Pneumonia (BOOP), and Other Late-Onset Noninfectious Pulmonary Complications following Allogeneic Hematopoietic Stem Cell Transplantation'. Together they form a unique fingerprint.

Cite this